---
created: '2026-02-09T05:54:31.589140Z'
description: The ratio of amyloid-beta 42 to amyloid-beta 40 peptides in CSF or plasma.
  A decreased ratio indicates amyloid pathology and is a core biomarker for Alzheimer's
  disease within the ATN framework.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/biomarker/amyloid-beta-4240-ratio/
slug: amyloid-beta-4240-ratio
tags:
- biomarker
- neurodegeneration
- alzheimers
- csf
- blood-test
- atn-framework
templateEngineOverride: njk
title: Amyloid-Beta 42/40 Ratio
type: biomarker
updated: '2026-02-09T05:54:31.589140Z'
---

{% raw %}
<h1>Amyloid-Beta 42/40 Ratio</h1>
<h2>Overview</h2>
<p>The Amyloid-Beta 42/40 ratio compares the concentrations of the 42-amino acid form (Aβ42) to the 40-amino acid form (Aβ40) of amyloid-beta peptides. In Alzheimer's disease, Aβ42 is preferentially deposited in brain plaques, causing a decrease in CSF and plasma Aβ42 relative to Aβ40. The ratio is more reliable than Aβ42 alone as it corrects for individual variation in total amyloid production.</p>
<h2>Why Ratio Is Superior to Aβ42 Alone</h2>
<ol>
<li><strong>Controls for production variability</strong>: Aβ40 reflects overall APP processing</li>
<li><strong>Reduces preanalytical variability</strong>: Less affected by tube binding, handling</li>
<li><strong>Better discrimination</strong>: Higher diagnostic accuracy for amyloid positivity</li>
<li><strong>Concordance with PET</strong>: Better correlation with amyloid PET imaging</li>
</ol>
<h2>Reference Values</h2>
<h3>CSF Aβ42/40 Ratio</h3>
<table>
<thead>
<tr>
<th>Status</th>
<th>Ratio</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&gt;0.089</td>
<td>Amyloid negative</td>
</tr>
<tr>
<td>Reduced</td>
<td>&lt;0.089</td>
<td>Amyloid positive</td>
</tr>
<tr>
<td>Borderline</td>
<td>0.085-0.089</td>
<td>Consider PET confirmation</td>
</tr>
</tbody>
</table>
<p><em>Cutoffs may vary by laboratory and assay platform</em></p>
<h3>Plasma Aβ42/40 Ratio</h3>
<ul>
<li>Platform-dependent; generally lower than CSF</li>
<li>Emerging for screening; less sensitive than CSF</li>
<li>Mass spectrometry methods show best performance</li>
</ul>
<h2>ATN Framework Role</h2>
<ul>
<li><strong>&quot;A&quot; Component</strong>: Indicates amyloid pathology</li>
<li>Combined with T (tau) and N (neurodegeneration) for staging</li>
<li>A+ indicates AD pathological change regardless of symptoms</li>
</ul>
<h2>Clinical Applications</h2>
<h3>Diagnostic Use</h3>
<ol>
<li><strong>Symptomatic patients</strong>: Confirms AD etiology of dementia/MCI</li>
<li><strong>Differential diagnosis</strong>: Distinguishes AD from non-AD dementias</li>
<li><strong>Preclinical research</strong>: Identifies at-risk individuals</li>
</ol>
<h3>Prognostic Use</h3>
<ul>
<li>Predicts conversion from MCI to AD dementia</li>
<li>Correlates with future cognitive decline in cognitively normal individuals</li>
<li>Amyloid positivity precedes symptoms by 15-20 years</li>
</ul>
<!-- NEO4J_CONTENT_START -->
<h2>Relationships</h2>
<h3>Related</h3>
<ul>
<li>→ [[Amyloid_PET_Imaging]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Amyloid-Beta_4240_Ratio]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Down_Syndrome]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Amyloid_Cascade]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Vascular_Dementia]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Neurofilament_Light_Chain]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Alzheimers_Disease]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Plasma_Amyloid-Beta_Ratio]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Total_Tau]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Cerebral_Amyloid_Angiopathy]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[MRI_Volumetry]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Lumbar_Puncture]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Mild_Cognitive_Impairment]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Sleep_Optimization]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Parkinsons_Disease]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Frontotemporal_Dementia]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Plasma_p-tau217]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:47:13.883320'
source: obsidian
</code></pre>
<ul>
<li>→ [[Down_Syndrome]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Cerebral_Amyloid_Angiopathy]] (entity)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Amyloid-Beta_4240_Ratio]] (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T06:03:01.894650'
source: obsidian
</code></pre>
<ul>
<li>← [[Amyloid_Cascade]] (pathway)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:08:11.155642'
source: obsidian
</code></pre>
<ul>
<li>→ [[Amyloid_PET_Imaging]] (examination)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Alzheimers_Disease]] (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Neurofilament_Light_Chain]] (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Mild_Cognitive_Impairment]] (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Total_Tau]] (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[MRI_Volumetry]] (examination)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Vascular_Dementia]] (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Frontotemporal_Dementia]] (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Parkinsons_Disease]] (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>→ [[Phospho-Tau]] (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:09.882854'
source: obsidian
</code></pre>
<ul>
<li>← [[Sleep_Optimization]] (intervention)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:48.863953'
source: obsidian
</code></pre>
<ul>
<li>← [[Lumbar_Puncture]] (examination)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:45.028418'
source: obsidian
</code></pre>
<ul>
<li>← [[Amyloid_PET_Imaging]] (examination)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:44.235597'
source: obsidian
</code></pre>
<ul>
<li>← [[Mild_Cognitive_Impairment]] (condition)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:33.408670'
source: obsidian
</code></pre>
<ul>
<li>← [[Total_Tau]] (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:17.683830'
source: obsidian
</code></pre>
<ul>
<li>← [[Plasma_p-tau217]] (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:16.234462'
source: obsidian
</code></pre>
<ul>
<li>← [[Plasma_Amyloid-Beta_Ratio]] (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:15.960616'
source: obsidian
</code></pre>
<ul>
<li>← [[Phospho-Tau]] (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:15.718126'
source: obsidian
</code></pre>
<ul>
<li>← [[Neurofilament_Light_Chain]] (biomarker)</li>
</ul>
<pre><code class="language-yaml">last_modified: '2026-01-26T07:07:15.198842'
source: obsidian
</code></pre>
<!-- NEO4J_CONTENT_END -->
<h2>Relationships</h2>
<h3>Conditions with Decreased Ratio</h3>
<ul>
<li>→ [[Alzheimer's Disease]] (condition) - <em>Core diagnostic biomarker</em></li>
<li>→ [[Mild Cognitive Impairment]] (condition) - <em>If progressing to AD</em></li>
<li>→ [[Down Syndrome]] (condition) - <em>Early amyloid deposition</em></li>
<li>→ [[Cerebral Amyloid Angiopathy]] (condition) - <em>Vascular amyloid</em></li>
</ul>
<h3>Conditions with Normal Ratio</h3>
<ul>
<li>→ [[Frontotemporal Dementia]] (condition) - <em>Usually normal</em></li>
<li>→ [[Parkinson's Disease]] (condition) - <em>Usually normal</em></li>
<li>→ [[Vascular Dementia]] (condition) - <em>Unless mixed with AD</em></li>
</ul>
<h3>Related Biomarkers</h3>
<ul>
<li>→ [[Phospho-Tau]] (biomarker) - <em>Tau pathology marker</em></li>
<li>→ [[Total Tau]] (biomarker) - <em>Neurodegeneration marker</em></li>
<li>→ [[Neurofilament Light Chain]] (biomarker) - <em>Axonal damage</em></li>
</ul>
<h3>Imaging Correlates</h3>
<ul>
<li>← [[Amyloid PET Imaging]] (examination) - <em>Direct plaque visualization</em></li>
<li>← [[MRI Volumetry]] (examination) - <em>Hippocampal atrophy</em></li>
</ul>
<h2>Sample Handling Considerations</h2>
<h3>Preanalytical Factors</h3>
<ul>
<li>Use polypropylene tubes (Aβ42 binds to polystyrene)</li>
<li>Process within specified time windows</li>
<li>Avoid freeze-thaw cycles</li>
<li>Follow laboratory-specific protocols</li>
</ul>
<h3>Diurnal Variation</h3>
<ul>
<li>Minimal clinically significant variation</li>
<li>Lumbar puncture timing flexible</li>
</ul>
<h2>Anti-Amyloid Therapy Monitoring</h2>
<ul>
<li>Ratio increases with successful amyloid-lowering treatment</li>
<li>Used as surrogate endpoint in clinical trials</li>
<li>Monitored alongside amyloid PET in treated patients</li>
</ul>
<h2>References</h2>
<ol>
<li><strong>Validation</strong>: Hansson, O., et al. (2019). &quot;CSF Aβ42/Aβ40 ratio.&quot; <em>Alzheimer's Research &amp; Therapy</em>.</li>
<li><strong>ATN Framework</strong>: Jack, C.R., et al. (2018). &quot;NIA-AA Research Framework.&quot; <em>Alzheimer's &amp; Dementia</em>.</li>
<li><strong>Plasma</strong>: Nakamura, A., et al. (2018). &quot;High-performance plasma amyloid-β biomarkers.&quot; <em>Nature</em>.</li>
</ol>

{% endraw %}